Bluejay Diagnostics (BJDX) Share-based Compensation Growth (1y) (2021 - 2025)
Bluejay Diagnostics (BJDX) Share-based Compensation Growth (1y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 9.69% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 3.57% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -4.08% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 12.16% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 12.94% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -30.44% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 26.61% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 59.09% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 31.63% |
| 10 | Bluejay Diagnostics | 4.43 Mn | 746,549.00 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 102.87% |
| Sep 30, 2025 | -96.18% |
| Jun 30, 2025 | -126.01% |
| Mar 31, 2025 | -88.95% |
| Dec 31, 2024 | 83.41% |
| Sep 30, 2024 | 111.28% |
| Jun 30, 2024 | -78.30% |
| Mar 31, 2024 | -94.59% |
| Dec 31, 2023 | -117.77% |
| Sep 30, 2023 | -137.52% |
| Jun 30, 2023 | -73.89% |
| Mar 31, 2023 | 74.16% |
| Dec 31, 2022 | 304.83% |
| Sep 30, 2022 | 143.46% |
| Jun 30, 2022 | 68,360.65% |
| Mar 31, 2022 | 76,781.71% |
| Dec 31, 2021 | 630.91% |
| Sep 30, 2021 | 643.94% |